Graft versus host disease following allogeneic stem cell transplantation research hub

Investigating the use of lenzilumab for acute graft versus host disease (when transplanted stem cells attack the body’s cells)

This UK clinical trial is testing a new drug called lenzilumab for acute graft versus host disease (GvHD). GvHD happens when transplanted donor cells attack the patient's body. Researchers want to see if adding lenzilumab to standard steroid treatment is safe and helps patients who have a higher risk of severe illness.